HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
WithdrawnNCT01567124

Alleviating the Metabolic Side Effects of Antipsychotic Medications

Medication studyAges 18–65AustraliaSchizophrenia
The study in practice

Understand this study

Who could participate?

This study is for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.

Listed locations
Ballarat and 3 more locationsSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateMay 2012
Recruitment status
Withdrawn
Enrollment listed in the registry
0
Sponsor
Baker Heart and Diabetes Institute
Sponsor type
Research institute
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
Australia
Age range
From 18 Years to 65 Years
Official registry ID
NCT01567124
Official title
Show the full official title

A Randomised Trial Examining the Effectiveness of Sympathetic Nervous Inhibition in Alleviating the Metabolic Side Effects of Antipsychotic Medications in Patients With Schizophrenia

Recruitment & locations

Withdrawn

Ballarat · Clayton · Melbourne

Checked Official study record (opens in a new tab)

A listed location does not confirm current availability.

FAQ

Questions about this study

Who is behind this study?

The study sponsor is Baker Heart and Diabetes Institute, a research institute.

Does this study involve medication?

Yes. The study involves medication, including Moxonidine and Placebo.

Who can participate?

This study is for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as withdrawn.

Want to explore more studies?

Explore studies